Systemic Mastocytosis
A rare clonal blood disorder where abnormal mast cells accumulate in the bone marrow and internal organs, releasing histamine and other chemicals that cause severe allergic-like symptoms and potential organ damage.
Emergency Management: Acute anaphylactic shock requiring standard ACLS protocols, aggressive IV fluid resuscitation (up to several liters), and continuous IV epinephrine infusion (0.1-0.5 mcg/kg/min).
Systemic mastocytosis (SM) is a rare, clonal neoplasm of mast cells characterized by the abnormal proliferation and accumulation of mast cells in various organs, most notably the bone marrow, skin, gastrointestinal tract, liver, and spleen. The neoplastic mast cells secrete vasoactive mediators, leading to complex allergic-type systemic symptoms and, in advanced forms, organ dysfunction.
Detailed Overview
The hallmark of SM is a somatic gain-of-function mutation in the KIT gene (predominantly the D816V mutation), which encodes a receptor tyrosine kinase. This mutation results in ligand-independent continuous activation of KIT, driving autonomous mast cell proliferation. The clinical presentation is extremely heterogeneous, ranging from indolent forms (ISM), which present merely with mediator-related symptoms and normal life expectancy, to advanced forms like mast cell leukemia (MCL) or SM with an associated hematological neoplasm (SM-AHN), which have significant morbidity and mortality.
Epidemiology & Demographics
A rare disease with an estimated prevalence of 10 to 13 per 100,000. It typically presents in adults (median age at diagnosis is 50-60 years). Pediatric mastocytosis is predominantly cutaneous and tends to regress by puberty, whereas adult-onset disease is almost always systemic and persistent.
Etiological Mechanism
Driven almost exclusively by an acquired somatic mutation in the KIT gene. The KIT D816V mutation is detected in >90% of adult patients with SM.
Primary Causes
The primary cause is the oncogenic KIT D816V mutation. Triggers for symptom flares (degranulation) include physical stimuli (heat, cold, friction), emotional stress, alcohol, insect venom, and certain drugs (NSAIDs, opioids, contrast media).
The mutated KIT receptor undergoes spontaneous autophosphorylation, promoting mast cell survival, proliferation, and resistance to apoptosis. The expanded clone of neoplastic mast cells infiltrates the bone marrow, spleen, and liver. Upon triggering, these cells degranulate excessively, releasing preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandin D2, leukotrienes, cytokines). Histamine causes flushing, hypotension, and gastric hypersecretion. Leukotrienes cause bronchoconstriction and cramping.
Diagnostic Criteria & Guidelines
WHO criteria require 1 major OR 3 minor criteria. Major: Multifocal dense infiltrates of >15 mast cells in bone marrow. Minor: 1) >25% of mast cells in marrow are atypical/spindle-shaped, 2) Detection of KIT D816V mutation, 3) Mast cells co-express CD2 and/or CD25, 4) Serum baseline tryptase >20 ng/mL.
For mediator symptoms: H1-antihistamines (Cetirizine 10-40 mg/day), H2-antihistamines (Famotidine 20-40 mg BID), and Mast cell stabilizers (Oral Cromolyn Sodium 200 mg QID). Epinephrine autoinjector (0.3 mg IM) must be carried at all times. For Advanced SM: Avapritinib (Ayvakit) 200 mg orally once daily (a potent selective KIT D816V inhibitor).
Second-Line & Adjunctive Therapy
For advanced SM unable to take Avapritinib: Midostaurin 100 mg orally BID. Cladribine (2-CdA) or Interferon-alpha for cytoreductive therapy in slow-progressing advanced cases. Omalizumab (Xolair) 150-300 mg SQ every 4 weeks for refractory anaphylaxis/urticaria.
Surgical & Procedural Management
Splenectomy may be considered for severe hypersplenism causing transfusion-dependent cytopenias in advanced SM.
Patient Counseling & Advice
Educate the patient extensively on recognizing the early signs of anaphylaxis and how to properly use an EpiPen. Advise that any new medication, contrast dye, or surgery must be cleared or premedicated (with antihistamines/corticosteroids) to prevent severe degranulation.
Follow-Up & Monitoring Schedule
Indolent SM: Annual monitoring with CBC, CMP, and serum tryptase; DEXA scan every 2-3 years. Advanced SM: Frequent hematologic monitoring (CBC monthly) and serial marrow biopsies to assess response to TKI therapy.
Preventive Strategies
Prophylactic administration of H1/H2 blockers and corticosteroids (e.g., Prednisone 50 mg) 12-24 hours prior to surgery, radiocontrast administration, or invasive dental procedures.
Indolent SM: Normal life expectancy. Advanced SM (ASM, SM-AHN, MCL): Poor prognosis without TKI therapy, with median survival ranging from 6 months (MCL) to 3-4 years (ASM).